Results 171 to 180 of about 15,943 (285)

A case report of MYH7 mutation-induced restrictive cardiomyopathy. [PDF]

Eur Heart J Case Rep
Zhang S, Zhao W.
europepmc   +1 more source

Echocardiographic Criteria to Differentiate Constrictive Pericarditis From Restrictive Cardiomyopathy: A Meta-analysis. [PDF]

CJC Open, 2023
Diaz-Arocutipa C, Chumbiauca M, Medina HM, Hernandez AV, Vicent L.   +4 more
europepmc   +1 more source

Novel drugs approved by the EMA, the FDA and the MHRA in 2025: A year in review

British Journal of Pharmacology, EarlyView.
Abstract In the 2025 novel drug mini‐review, one can take a full measure of the ingenuity that underlies current drug design and development, despite the year's smaller harvest (46 novel drugs) compared to 2024 (53) and 2023 (70). 54% of the novel drugs are first‐in‐class (FIC).
Andreas Papapetropoulos, Stavros Topouzis, Steve P. H. Alexander, Miriam M. Cortese‐Krott, Zsuzsanna Helyes, Kirill Martemyanov, Claudio Mauro, Nithyanandan Nagercoil, Reynold A. Panettieri Jr, Hemal H. Patel, Rainer Schulz, Barbara Stefanska, Gary J. Stephens, Nathalie Vergnolle, Xin Wang, Stephen Ward, Péter Ferdinandy   +16 more
wiley   +1 more source

Impact of Increasing Referral for ^99mTc-DPD Scintigraphy on Prognosis Across the Phenotypic Spectrum of Restrictive Cardiomyopathy. [PDF]

JACC Adv
Choy CH, Kwok CS, Wahid Y, Liu B, Turvey-Haigh L, Parker K, Cullis J, Parekh P, Hussain K, Akhtar A, Bradlow WM, Zaphiriou A, Baig S, Gillmore JD, Fontana M, Pinney J, Steeds RP, Moody WE.   +17 more
europepmc   +1 more source

Genetic Insights into Primary Restrictive Cardiomyopathy. [PDF]

J Clin Med, 2022
Brodehl A, Gerull B.
europepmc   +1 more source

Restrictive Cardiomyopathy: Contemporary Insights into Pathophysiology, Diagnostic Complexity, and Evolving Therapeutic Perspectives

Universidad Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, Mexico., R Munoz, D Ramirez, Universidad Universidad Cuauhtémoc Plantel Aguascalientes. Aguascalientes, Mexico., Ángel Alemán Márquez, Universidad Autónoma de Aguascalientes. Aguascalientes, Mexico., D. Hernandez, Centro Universitario de Estudios de la Salud de Aguascalientes. Aguascalientes, Mexico., Oswald Gerardo Mauricio Cruz, Centro Universitario de Estudios de la Salud de Aguascalientes. Aguascalientes, Mexico., A. Esparza, Centro Universitario de Estudios de la Salud de Aguascalientes. Aguascalientes, Mexico., Brenna Costa da Silva, Universidad Cuauhtemoc Aguascalientes. Aguascalientes, Mexico., Katia Gabriela Silva Esquivel, Universidad Cuauhtemoc Aguascalientes. Aguascalientes, Mexico., Miguel Á. Contreras, Universidad de Guadalajara. Guadalajara, Jalisco, Mexico., C Curiel, Universidad del Valle de Atemajac. Mexico., S. Reyes, Universidad Autónoma de Aguascalientes. Aguascalientes, Mexico.   +21 more
openalex   +2 more sources

Second‐generation prokineticin PKR1 receptor agonists: Advancing cardioprotection against chemotherapy‐induced toxicity

British Journal of Pharmacology, EarlyView.
IS39, a novel non‐peptide PKR1 agonist, confers cardioprotection against doxorubicin‐induced toxicity. IS39 activates PKR1‐mediated pro‐survival signalling in cardiomyocytes, reducing reactive oxygen species (ROS), DNA damage and fibrosis markers. In vivo, IS39 preserves cardiac geometry and function in mice exposed to chronic doxorubicin challenge ...
Anais Audebrand, Simone Brogi, Mustafa Tezeren, Andrea Tafi, Omer H. Ocak, Hasan Koyuncu, Igor Tetko, Laurent Désaubry, Canan G. Nebigil   +8 more
wiley   +1 more source

Comparing the Efficacy of Myosin Inhibition Versus Thin Filament Calcium Desensitization for Treatment of Pediatric Restrictive Cardiomyopathy Using a Patient-Derived hiPSC Model. [PDF]

Circ Genom Precis Med
Staudt DW, Serrano R, Hnatiuk AP, Sanchez I, Carhuamaca X, Feyen DAM, Mercola M.   +6 more
europepmc   +1 more source

A Volume Challenge Reveals the Diagnosis of Pediatric Restrictive Cardiomyopathy. [PDF]

Case Rep Cardiol, 2022
Cohen E, O'Halloran CP, Thrush PT, Ma TM, Tannous P.   +4 more
europepmc   +1 more source

Circulating Musclin is associated with skeletal muscle function and subclinical cardiac dysfunction in patients with cancer

British Journal of Pharmacology, EarlyView.
Background and Purpose Musclin (osteocrin) is a skeletal muscle‐derived peptide that has been implicated in cardioprotective signalling pathways. Its relevance in cancer patients, who frequently experience muscle wasting and cardiotoxicity, remains unclear. This study aimed to determine whether circulating Musclin levels reflect functional capacity and
Jannek Brauer, Daniel Finke, Sebastian Romann, Norbert Frey, Joerg Heineke, Lorenz H. Lehmann   +5 more
wiley   +1 more source